MXPA02012256A - Proteinas v de morbillivirus modificados. - Google Patents

Proteinas v de morbillivirus modificados.

Info

Publication number
MXPA02012256A
MXPA02012256A MXPA02012256A MXPA02012256A MXPA02012256A MX PA02012256 A MXPA02012256 A MX PA02012256A MX PA02012256 A MXPA02012256 A MX PA02012256A MX PA02012256 A MXPA02012256 A MX PA02012256A MX PA02012256 A MXPA02012256 A MX PA02012256A
Authority
MX
Mexico
Prior art keywords
modified
morbillivirus
morbilliviruses
amino acids
mutated
Prior art date
Application number
MXPA02012256A
Other languages
English (en)
Inventor
Christopher L Parks
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of MXPA02012256A publication Critical patent/MXPA02012256A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18461—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a Morbillivirus modificados que tienen al menos una mutacion en la region correspondiente a los aminoacidos 112-134 de la proteina V del virus de sarampion, en donde uno o ambos de los aminoacidos 113 o 114 esta mutado. Tales Morbillivirus modificados exhiben una represion reducida de la expresion del gen. Las mutaciones o supresiones adicionales en otras regiones del genoma pueden ser incluidas, incluyendo en la region carboxi-terminal.
MXPA02012256A 2000-06-23 2001-06-21 Proteinas v de morbillivirus modificados. MXPA02012256A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21365500P 2000-06-23 2000-06-23
PCT/US2001/019806 WO2002000694A2 (en) 2000-06-23 2001-06-21 Modified morbillivirus v proteins

Publications (1)

Publication Number Publication Date
MXPA02012256A true MXPA02012256A (es) 2003-04-25

Family

ID=22795965

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012256A MXPA02012256A (es) 2000-06-23 2001-06-21 Proteinas v de morbillivirus modificados.

Country Status (17)

Country Link
US (1) US6664066B2 (es)
EP (1) EP1292615B1 (es)
JP (1) JP2004513616A (es)
KR (1) KR100885325B1 (es)
CN (1) CN1298738C (es)
AT (1) ATE343589T1 (es)
AU (2) AU6701401A (es)
BR (1) BR0111827A (es)
CA (1) CA2409432C (es)
CY (1) CY1105842T1 (es)
DE (1) DE60124098T2 (es)
DK (1) DK1292615T3 (es)
ES (1) ES2273852T3 (es)
IL (1) IL153004A0 (es)
MX (1) MXPA02012256A (es)
PT (1) PT1292615E (es)
WO (1) WO2002000694A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50214200D1 (de) 2001-06-05 2010-03-25 Curevac Gmbh Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
CA2528002A1 (en) 2003-06-09 2004-12-29 Wyeth Improved method for the recovery of non-segmented, negative-stranded rna viruses from cdna
DE102004042546A1 (de) * 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
JP2010507361A (ja) 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
EP2069485A4 (en) * 2007-07-13 2011-05-25 Medimmune Llc PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
US9226959B2 (en) 2008-01-31 2016-01-05 Curevac Ag Nucleic acids comprising formula (NuGlXmGnNv)a and derivatives thereof as immunostimulating agent/adjuvant
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
EP2449113B8 (en) 2010-07-30 2015-11-25 CureVac AG Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
CN104471064B (zh) * 2012-01-20 2018-11-02 中华人民共和国香港特别行政区政府 副粘病毒及其用途
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
MX369469B (es) 2013-08-21 2019-11-08 Curevac Ag Vacuna contra el virus respiratorio sincitial.
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
CN106537444A (zh) 2014-05-06 2017-03-22 埃尔瓦有限公司 用于要求至少一个运输车辆单元的出行计划的系统和方法
US10458801B2 (en) 2014-05-06 2019-10-29 Uber Technologies, Inc. Systems and methods for travel planning that calls for at least one transportation vehicle unit
US9552559B2 (en) 2014-05-06 2017-01-24 Elwha Llc System and methods for verifying that one or more directives that direct transport of a second end user does not conflict with one or more obligations to transport a first end user
EP3169701B1 (en) * 2014-07-18 2020-06-10 Institut National de la Santé et de la Recherche Medicale Peptides including a binding domain of the viral phosphoprotein (p) subunit to the viral rna free nucleoprotein (n0)
WO2016029168A1 (en) 2014-08-21 2016-02-25 Uber Technologies, Inc. Arranging a transport service for a user based on the estimated time of arrival of the user
US10685416B2 (en) 2015-12-10 2020-06-16 Uber Technologies, Inc. Suggested pickup location for ride services
US10731998B2 (en) 2017-11-05 2020-08-04 Uber Technologies, Inc. Network computer system to arrange pooled transport services

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69532369T3 (de) 1994-07-18 2010-11-04 Conzelmann, Karl-Klaus, Prof. Dr. Rekombinantes infektiöses nicht-in-Segmente-geteiltes, negativ-Strange-RNS-Virus
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
EP0932684A2 (en) * 1996-09-27 1999-08-04 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
ATE501259T1 (de) 1997-05-23 2011-03-15 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
JP2002507408A (ja) 1998-03-26 2002-03-12 アメリカン・サイアナミド・カンパニー 麻疹ウイルスもしくはヒト呼吸合胞体ウイルスサブグループｂの弱毒化の原因である突然変異

Also Published As

Publication number Publication date
DE60124098T2 (de) 2007-04-05
CA2409432A1 (en) 2002-01-03
CA2409432C (en) 2010-08-03
BR0111827A (pt) 2003-05-20
JP2004513616A (ja) 2004-05-13
IL153004A0 (en) 2003-06-24
EP1292615B1 (en) 2006-10-25
AU2001267014B2 (en) 2007-03-15
CN1437613A (zh) 2003-08-20
KR100885325B1 (ko) 2009-02-25
WO2002000694A2 (en) 2002-01-03
US20030206925A1 (en) 2003-11-06
DE60124098D1 (de) 2006-12-07
EP1292615A2 (en) 2003-03-19
CY1105842T1 (el) 2011-02-02
AU6701401A (en) 2002-01-08
ES2273852T3 (es) 2007-05-16
ATE343589T1 (de) 2006-11-15
KR20030032971A (ko) 2003-04-26
PT1292615E (pt) 2007-01-31
DK1292615T3 (da) 2007-02-19
US6664066B2 (en) 2003-12-16
CN1298738C (zh) 2007-02-07
WO2002000694A3 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
MXPA02012256A (es) Proteinas v de morbillivirus modificados.
ATE321867T1 (de) Zusammensetzungen und methoden zur verwendung von dna polymerasen
EP1322307A4 (en) METHODS OF TREATING CELL PROLIFERATION DISORDERS AND VIRAL INFECTIONS
MX343744B (es) Antigenos de neisseria meningitidis y composiciones que los contienen.
ATE79138T1 (de) Typenspezifische papillomavirus-dns-sequenzen und peptide.
ATE237312T1 (de) In liposomen verkapselte nukleinsäurekomplexe
BR9914374A (pt) Sequências genÈmicas de neisseria e métodos para seu uso
ATE185572T1 (de) Kombinatorische pna-bibliotheken und verbesserte syntheseverfahren
DE69935986D1 (de) Streptococcus pneumoniae proteine und nukleinsäuren
DE69941701D1 (de) Mutanten von flt3-l und ihre verwendungen
TR200001709T2 (tr) Yeni neisseria meningitids yüzey proteini
DE60110564D1 (en) Rna polymerase mutanten mit erhöhter thermostabilität
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
CA2353792A1 (en) Mutants of rna polymerases with increased stability
EP1064296A4 (en) THERMOSTABLE DNA POLYMERASE FROM THERMOANAEROBACTER THERMOHYDROSULFURICUS
DE69736801D1 (de) Gereinigte proteine, rekombinante dns-sequenzen und prozesse für die produktion von koffeinfreien getränken
DK1294874T3 (da) CD154-varianter og anvendelser deraf
WO2001064888A3 (en) Kunitz domain polypeptide zkun8
MXPA01009335A (es) Proteinas recombinantes de adhesiva de haemophilus influenzae.
ATE373095T1 (de) Mutierte muskelspezifische enhancer
WO2003100075A3 (en) Bsnd nucleic acids and proteins
WO2002079459A3 (en) Means for inhibiting proteolytical processing of parkin
Marusich et al. Nucleotide and deduced amino acid sequences of bacteriophage T4 gene 22.
WO2004018702A3 (en) Nphp nucleic acids and proteins
Zylicz et al. Properties of the purified dnaK gene product of Escherichia coli.

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration